PE20211774A1 - Piridazinonas y sus metodos de uso - Google Patents
Piridazinonas y sus metodos de usoInfo
- Publication number
- PE20211774A1 PE20211774A1 PE2021000320A PE2021000320A PE20211774A1 PE 20211774 A1 PE20211774 A1 PE 20211774A1 PE 2021000320 A PE2021000320 A PE 2021000320A PE 2021000320 A PE2021000320 A PE 2021000320A PE 20211774 A1 PE20211774 A1 PE 20211774A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrogen
- pyridazinones
- methods
- fluorophenyl
- double bond
- Prior art date
Links
- -1 cyclopropane-1,1-diyl Chemical group 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de formula (I) donde "--- " es un enlace simple o enlace doble, X1 puede ser CH, N; X 2 puede ser CH o N, N (CH3) entre otros; Y puede ser -0-, ciclopropano-1, 1-diilo entre otros, Q es 2-trifluorometil-4-fluorofenilo, 2-difluorometil-4-fluorofenilo; R 3 es hidrogeno; y cuando "--- " es un enlace doble, R 4 esta ausente; y cuando "--- " es un enlace sencillo, R 3 y R 4 se toman juntos para formar = 0; y cada uno de R 5 y R 6 es independientemente hidrogeno o -CH 3 ,siempre que si X 1 es N, X 2 es N, Y es -O- o -N (CH 3 ) - y Q es 2-trifluorometilfenilo, entonces al menos uno de R 3 , R 5 y R 6 no es hidrogeno. Composiciones farmaceuticas relacionadas. Tambien se utilizan para tratar enfermedades renales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732728P | 2018-09-18 | 2018-09-18 | |
| US201862780553P | 2018-12-17 | 2018-12-17 | |
| PCT/US2019/051680 WO2020061162A1 (en) | 2018-09-18 | 2019-09-18 | Pyridazinones and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211774A1 true PE20211774A1 (es) | 2021-09-08 |
Family
ID=69887813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000320A PE20211774A1 (es) | 2018-09-18 | 2019-09-18 | Piridazinonas y sus metodos de uso |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10654850B2 (es) |
| EP (1) | EP3852533B1 (es) |
| JP (1) | JP7474243B2 (es) |
| KR (1) | KR20210069652A (es) |
| CN (1) | CN112911935A (es) |
| AU (1) | AU2019344928A1 (es) |
| BR (1) | BR112021004926A2 (es) |
| CA (1) | CA3113236A1 (es) |
| CL (1) | CL2021000648A1 (es) |
| CO (1) | CO2021004789A2 (es) |
| DK (1) | DK3852533T3 (es) |
| EC (1) | ECSP21026485A (es) |
| FI (1) | FI3852533T3 (es) |
| IL (1) | IL281438B2 (es) |
| LT (1) | LT3852533T (es) |
| MX (1) | MX2021003152A (es) |
| PE (1) | PE20211774A1 (es) |
| PH (1) | PH12021550443A1 (es) |
| PT (1) | PT3852533T (es) |
| SG (1) | SG11202102053VA (es) |
| TW (1) | TWI828758B (es) |
| UY (1) | UY38377A (es) |
| WO (1) | WO2020061162A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10654850B2 (en) | 2018-09-18 | 2020-05-19 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| WO2020206623A1 (en) | 2019-04-10 | 2020-10-15 | Goldfinch Bio, Inc. | Crystal forms |
| WO2022006278A1 (en) * | 2020-07-01 | 2022-01-06 | Angion Biomedica Corp. | Reducing fibrosis and treating related diseases, disorders, and conditions |
| EP4174069A1 (en) * | 2020-07-03 | 2023-05-03 | Wuhan LL Science and Technology Development Co., Ltd. | Heterocyclic compound and use thereof |
| CN114907408B (zh) * | 2021-02-07 | 2024-05-03 | 武汉朗来科技发展有限公司 | 一种杂环化合物、其中间体、其制备方法及其应用 |
| CN117940417A (zh) * | 2021-09-10 | 2024-04-26 | 南京明德新药研发有限公司 | 卤素取代的哒嗪酮类化合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA77526C2 (en) | 2002-06-07 | 2006-12-15 | Sanofi Aventis | Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy |
| WO2005070929A1 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7491713B2 (en) | 2004-01-29 | 2009-02-17 | Merck + Co., Inc. | CGRP receptor antagonists |
| DE102004044231A1 (de) | 2004-09-14 | 2006-03-16 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| CA2583536A1 (en) | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
| ES2397283T3 (es) | 2006-07-25 | 2013-03-06 | Cephalon, Inc. | Derivados de piridizinona |
| WO2008115385A2 (en) | 2007-03-15 | 2008-09-25 | Schering Corporation | Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors |
| MX2010004705A (es) * | 2007-10-31 | 2010-05-27 | Nissan Chemical Ind Ltd | Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7. |
| US8633233B2 (en) * | 2008-08-06 | 2014-01-21 | Hydra Biosciences, Inc. | Methods and compositions for treating anxiety |
| KR20180031823A (ko) * | 2010-09-01 | 2018-03-28 | 질레드 코네티컷 인코포레이티드 | 피리다지논, 그의 제조 방법 및 사용 방법 |
| CA2874953A1 (en) * | 2012-06-12 | 2013-12-19 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| JP6667093B2 (ja) | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体 |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| CA3075727A1 (en) | 2017-09-18 | 2019-03-21 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| US10703748B2 (en) | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
| US10654850B2 (en) | 2018-09-18 | 2020-05-19 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| AU2020240059A1 (en) * | 2019-03-20 | 2021-10-28 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| WO2020206623A1 (en) * | 2019-04-10 | 2020-10-15 | Goldfinch Bio, Inc. | Crystal forms |
-
2019
- 2019-09-18 US US16/575,161 patent/US10654850B2/en active Active
- 2019-09-18 JP JP2021510041A patent/JP7474243B2/ja active Active
- 2019-09-18 BR BR112021004926-6A patent/BR112021004926A2/pt unknown
- 2019-09-18 PT PT198634818T patent/PT3852533T/pt unknown
- 2019-09-18 DK DK19863481.8T patent/DK3852533T3/da active
- 2019-09-18 CA CA3113236A patent/CA3113236A1/en active Pending
- 2019-09-18 TW TW108133609A patent/TWI828758B/zh active
- 2019-09-18 UY UY0001038377A patent/UY38377A/es unknown
- 2019-09-18 WO PCT/US2019/051680 patent/WO2020061162A1/en unknown
- 2019-09-18 MX MX2021003152A patent/MX2021003152A/es unknown
- 2019-09-18 LT LTEPPCT/US2019/051680T patent/LT3852533T/lt unknown
- 2019-09-18 KR KR1020217010630A patent/KR20210069652A/ko unknown
- 2019-09-18 SG SG11202102053VA patent/SG11202102053VA/en unknown
- 2019-09-18 CN CN201980060868.1A patent/CN112911935A/zh active Pending
- 2019-09-18 FI FIEP19863481.8T patent/FI3852533T3/fi active
- 2019-09-18 EP EP19863481.8A patent/EP3852533B1/en active Active
- 2019-09-18 IL IL281438A patent/IL281438B2/en unknown
- 2019-09-18 AU AU2019344928A patent/AU2019344928A1/en active Pending
- 2019-09-18 PE PE2021000320A patent/PE20211774A1/es unknown
-
2020
- 2020-05-18 US US16/876,599 patent/US11046690B2/en active Active
-
2021
- 2021-03-02 PH PH12021550443A patent/PH12021550443A1/en unknown
- 2021-03-16 CL CL2021000648A patent/CL2021000648A1/es unknown
- 2021-04-15 CO CONC2021/0004789A patent/CO2021004789A2/es unknown
- 2021-04-15 EC ECSENADI202126485A patent/ECSP21026485A/es unknown
- 2021-06-28 US US17/360,303 patent/US20220024917A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210069652A (ko) | 2021-06-11 |
| CN112911935A (zh) | 2021-06-04 |
| PT3852533T (pt) | 2024-05-31 |
| DK3852533T3 (da) | 2024-05-27 |
| JP7474243B2 (ja) | 2024-04-24 |
| EP3852533A1 (en) | 2021-07-28 |
| WO2020061162A1 (en) | 2020-03-26 |
| EP3852533B1 (en) | 2024-02-28 |
| CO2021004789A2 (es) | 2021-07-30 |
| FI3852533T3 (fi) | 2024-05-24 |
| LT3852533T (lt) | 2024-06-10 |
| IL281438B1 (en) | 2023-08-01 |
| CA3113236A1 (en) | 2020-03-26 |
| UY38377A (es) | 2020-04-30 |
| US20220024917A1 (en) | 2022-01-27 |
| CL2021000648A1 (es) | 2021-08-06 |
| TW202035402A (zh) | 2020-10-01 |
| BR112021004926A2 (pt) | 2021-06-01 |
| US10654850B2 (en) | 2020-05-19 |
| JP2022500359A (ja) | 2022-01-04 |
| AU2019344928A1 (en) | 2021-04-29 |
| US11046690B2 (en) | 2021-06-29 |
| IL281438A (en) | 2021-04-29 |
| MX2021003152A (es) | 2021-06-23 |
| SG11202102053VA (en) | 2021-04-29 |
| TWI828758B (zh) | 2024-01-11 |
| US20200283437A1 (en) | 2020-09-10 |
| EP3852533A4 (en) | 2022-06-15 |
| IL281438B2 (en) | 2023-12-01 |
| ECSP21026485A (es) | 2021-07-30 |
| US20200102301A1 (en) | 2020-04-02 |
| PH12021550443A1 (en) | 2021-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211774A1 (es) | Piridazinonas y sus metodos de uso | |
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| AR120080A1 (es) | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos | |
| CO2021016015A2 (es) | Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas | |
| UY38979A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| UY38525A (es) | 1,3,4-oxadiazoles y derivados de éstos como nuevos agentes fungicidas | |
| AR090670A1 (es) | Compuestos herbicidas | |
| BR112015011760A2 (pt) | composto, uso do composto, e uso de uma composição farmacêutica | |
| UY29818A1 (es) | Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos | |
| EA202192405A1 (ru) | Составы антител против il-36r | |
| PE20221901A1 (es) | Un compuesto aromatico sustituido con anillo fundido, metodo de preparacion, composicion herbicida y su uso | |
| EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
| ECSP21068097A (es) | Anticuerpos claudina 6 y usos de los mismos | |
| EA202192845A1 (ru) | Новые композиции, содержащие мелфлуфен | |
| BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
| BR112021020027A2 (pt) | Compostos, composições e métodos | |
| CO2022004341A2 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| PA8782901A1 (es) | "nuevos compuestos ligandos del receptor de la adenosina a3" | |
| CO2022004391A2 (es) | Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4 | |
| CL2019002661A1 (es) | Compuestos antineoplásicos. | |
| PE20210550A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico | |
| ECSP099679A (es) | Nuevos compuestos y sus usos 707 | |
| CL2021003228A1 (es) | Compuestos tricíclicos y su uso | |
| CL2021002501A1 (es) | Compuestos novedosos y métodos de uso de los mismos. |